Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
Ilia L. Ferrusi, PhD(c)
Advertisement
Articles by Ilia L. Ferrusi, PhD(c)
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Daraxonrasib Clears FDA as First RAS-Targeted Pancreatic Cancer Drug
2
FDA Clears First Single-Biomarker Blood Test for Alzheimer
3
New York Experts Push for Coordinated Obesity Care Teams
4
Grocery Assistance Benefit Linked to Fewer Diabetes Complications
5